Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Cost of sales — Total: $93M in Q2 2026, down 21.8% from a year earlier.
Latest, Q2 2026
93
Period ended Jun 30, 2026
Change on a year earlier
-21.8%
119 in Q2 2025
History
26 quarters
Since Q1 2020
Sources
21
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Consolidated Statements of Operations, MD&A & Note 6.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up cost of sales — Total
- Cost of sales as % of net product sales (%)74.0% · Q2 2026
- Third-party royalties & milestone payments included in cost of sales ($M)11 · Q2 2026
- Inventory write-downs (excess & expiring shelf-life vaccines/raw materials) ($M)41 · Q2 2026
- Unutilized manufacturing capacity & CMO wind-down charges ($M)23 · Q2 2026
- Losses on firm purchase commitments & CMO cancellation fees ($M)0 · Q2 2026
- Stock-based compensation expense in cost of sales ($M)13 · Q2 2026
Cite this data
StockData. (2026). Moderna Cost of sales — Total ($M), quarterly Q1 2020–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/cos-total
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.